Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | PRKACA | P17612 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | CCR1 | P32246 | 3/20 | 0.61 |
| ▸ | CCR5 | P51681 | 3/20 | 0.61 |
| ▸ | CCR8 | P51685 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | ALPL | P05186 | 1/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | ALPG | P10696 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462395 | 1.00 | HSP90AA1 (0.62) | HSP90AA1AURKAPRKACAADORA2AKDM4E | |
| SCHEMBL28586950 | 0.98 | HSP90AA1 (0.60) | HSP90AA1AURKAPRKACAADORA2AKDM4E | |
| SCHEMBL23071629 | 0.85 | HSP90AA1 (0.63) | HSP90AA1AURKAPRKACAADORA2AKDM4E | |
| Dipyridyl SCHEMBL29167113 | 0.82 | KDM4E (0.79) | HSP90AA1KDM4ELMNAALOX15L3MBTL1 | |
| SCHEMBL1181563 | 0.82 | KDM4E (0.88) | HSP90AA1KDM4ELMNAALOX15L3MBTL1 | |
| SCHEMBL12436463 | 0.81 | KDM4E (0.64) | HSP90AA1AURKAPRKACAADORA2AKDM4E | |
| SCHEMBL3036765 | 0.79 | KDM4E (0.82) | HSP90AA1KDM4ELMNAALOX15L3MBTL1 | |
| SCHEMBL8348969 | 0.79 | KDM4E (0.61) | HSP90AA1KDM4ELMNAALOX15L3MBTL1 | |
| SCHEMBL776048 | 0.78 | KDM4E (0.67) | HSP90AA1KDM4ELMNAALOX15L3MBTL1 | |
| SCHEMBL27476056 | 0.78 | HSP90AA1 (0.61) | HSP90AA1AURKAPRKACAADORA2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110357907-B | Preparation method and application of 4, 6-di (pyridine-2-yl) pyrimidine-2-amine copper complex | 聊城大学 | 2021-07-27 | — | — | CN | claimed |
| CN-108126757-B | Preparation method and application of silver modified phosphorus-tungsten-oxygen cluster catalyst | 聊城大学 | 2020-09-01 | — | — | CN | claimed |
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-102432634-A | 2-amino-4- (2' -pyridine) -pyrimidine diperoxovanadium ammonium salt complex and single crystal culture and application thereof | UNIV HENAN SCIENCE & TECH | 2012-05-02 | — | — | CN | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | claimed |
| EP-3986553-B1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2026047630-A1 | HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS | HETERO LABS LIMITED (IN) | 2026-03-05 | — | — | WO | disclosed |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-11 | — | — | US | disclosed |
| US-12435057-B2 | Triazole carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-07 | — | — | US | disclosed |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2025015429-A1 | IMIDAZOPYRIMIDINE-BASED MULTIMETALLIC CATALYSTS | SCHIPPER DEREK JAMES (CA) | 2025-01-23 | — | — | WO | disclosed |
| US-6620818-B1 | Administering indolin-2-one derivative as cyclin-dependent kinase inhibitor | SMITHKLINE BEECHAM CORPORATION | 2003-09-16 | — | — | US | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-0150206-A4 | PYRIDINYL-2-PYRIMIDINAMINES USEFUL AS CARDIOTONICS AND PREPARATION THEREOF. | STERLING DRUG INC (US) | 1986-03-18 | — | — | EP | disclosed |
| EP-0150206-A1 | PYRIDINYL-2-PYRIMIDINAMINES USEFUL AS CARDIOTONICS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1985-08-07 | — | — | EP | disclosed |
| WO-1985000604-A1 | PYRIDINYL-2-PYRIMIDINAMINES USEFUL AS CARDIOTONICS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1985-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | LPAR1, LPAR5, LPAR2 | HSP90AA1 4454/4885AURKA 1623/4885PRKACA 2823/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | HSP90AA1 995/4885AURKA 653/4885PRKACA 213/4885 |
| US-12435057-B2 | Triazole carboxylic acids as LPA antagonists | LPAR3, LPAR1, LPAR5 | HSP90AA1 4494/4885AURKA 739/4885PRKACA 3183/4885 |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | LPAR1, LPAR3, LPAR2 | HSP90AA1 4352/4885AURKA 826/4885PRKACA 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.